 | |
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | TNF alpha |
| Clinical data | |
| Trade names | Humira, Mabura, Exemptia, others |
| Other names | adalimumab-adaz, adalimumab-adbm, adalimumab-afzb, adalimumab-atto, adalimumab-bwwd, adalimumab-fkjp |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a603010 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | Subcutaneous |
| Drug class | TNF inhibitor |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 64% (subcutaneous), 0% (By mouth) |
| Elimination half-life | 10–20 days |
| Chemical and physical data | |
| Formula | C6428H9912N1694O1987S46 |
| Molar mass | 144190.3 g·mol−1 |
| 3D model (JSmol) | |
| |
  (what is this?) (verify) | |
Adalimumab, sold under the brand name Humira among others, is a medication used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, psoriasis, hidradenitis suppurativa, uveitis, and juvenile idiopathic arthritis.[2][3][4] Use is generally only recommended in people who have not responded to other treatments.[3] It is used by injection under the skin.[2]
Common side effects include upper respiratory tract infections, pain at the site of injection, rash, and headache.[2] Other side effects may include serious infections, cancer, anaphylaxis, reactivation of hepatitis B, multiple sclerosis, heart failure, liver failure, and aplastic anemia.[2] Use during pregnancy is not recommended, while some feel use during breastfeeding may be safe.[3][6] Adalimumab is a disease-modifying antirheumatic drug and monoclonal antibody that works by inactivating tumor necrosis factor-alpha (TNFα).[2]
Adalimumab was approved for medical use in the United States in 2002.[7][2] It is on the World Health Organization's List of Essential Medicines.[8] It is expensive.[9] A month supply in the United Kingdom costs the NHS about £704 as of 2018.[3] In the United States the wholesale cost of this amount is about US$5,041.[10] In 2014, a biosimilar came to market in India at a price of US$400 per month,[11] and biosimilars are now available in the USA and Europe.[12] In 2017, it was the 169th most commonly prescribed medication in the United States, with more than three million prescriptions.[13][14]
References edit
- ^ a b Use During Pregnancy and Breastfeeding
- ^ a b c d e f g h "Adalimumab Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. 14 May 2018. Archived from the original on 21 November 2020. Retrieved 18 March 2019.
- ^ a b c d e British national formulary: BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 1074. ISBN 9780857113382.
- ^ a b "FDA Clears Adalimumab (Humira) for Hidradenitis Suppurativa". Medscape. 11 September 2015. Archived from the original on 21 January 2021. Retrieved 13 October 2017.
- ^ "WHOCC - ATC/DDD Index". www.whocc.no. Archived from the original on 31 October 2020. Retrieved 7 September 2020.
- ^ "Adalimumab Pregnancy and Breastfeeding Warnings". Drugs.com. Archived from the original on 17 April 2021. Retrieved 19 March 2019.
- ^ "Drug Approval Package: Humira (adalimumab)". U.S. Food and Drug Administration (FDA). 7 April 2017. Archived from the original on 18 February 2020. Retrieved 18 February 2020.
- ^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- ^ Hitchings, Andrew; Lonsdale, Dagan; Burrage, Daniel; Baker, Emma (2022). "Monoclonal antibodies". The Top 100 Drugs (3rd ed.). Elsevier Health Sciences. pp. 166–167. ISBN 978-0-323-83445-2. Archived from the original on 19 September 2023. Retrieved 18 September 2023.
- ^ "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services. Archived from the original on 6 March 2019. Retrieved 3 March 2019.
- ^ "India's Cadila launches first cheaper copy of world's top-selling drug". Reuters. 9 December 2014. Archived from the original on 27 March 2019. Retrieved 19 March 2019.
- ^ Peyrin-Biroulet L, Danese S, Cummings F, Atreya R, Greveson K, Pieper B, et al. (26 July 2019). "Anti-TNF biosimilars in Crohn's Disease: a patient-centric interdisciplinary approach". Expert Review of Gastroenterology & Hepatology. 13 (8): 731–738. doi:10.1080/17474124.2019.1645595. ISSN 1747-4124. PMID 31322440.
- ^ "The Top 300 of 2020". ClinCalc. Archived from the original on 18 March 2020. Retrieved 11 April 2020.
- ^ "Adalimumab - Drug Usage Statistics". ClinCalc. Archived from the original on 8 July 2020. Retrieved 11 April 2020.